United Therapeutics Corporation $UTHR Shares Sold by AustralianSuper Pty Ltd

AustralianSuper Pty Ltd trimmed its holdings in United Therapeutics Corporation (NASDAQ:UTHR) by 66.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 98,000 shares of the biotechnology company’s stock after selling 189,845 shares during the quarter. AustralianSuper Pty Ltd owned about 0.23% of United Therapeutics worth $41,083,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. F m Investments LLC lifted its position in United Therapeutics by 1.3% in the second quarter. F m Investments LLC now owns 2,580 shares of the biotechnology company’s stock worth $741,000 after purchasing an additional 33 shares during the period. HB Wealth Management LLC boosted its stake in United Therapeutics by 2.9% during the second quarter. HB Wealth Management LLC now owns 1,235 shares of the biotechnology company’s stock valued at $355,000 after buying an additional 35 shares in the last quarter. WealthCollab LLC raised its position in United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 38 shares in the last quarter. Coldstream Capital Management Inc. lifted its holdings in United Therapeutics by 2.0% in the 2nd quarter. Coldstream Capital Management Inc. now owns 2,145 shares of the biotechnology company’s stock valued at $616,000 after acquiring an additional 43 shares during the last quarter. Finally, Trail Ridge Investment Advisors LLC boosted its position in shares of United Therapeutics by 2.0% during the 3rd quarter. Trail Ridge Investment Advisors LLC now owns 2,256 shares of the biotechnology company’s stock valued at $946,000 after purchasing an additional 44 shares in the last quarter. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Stock Down 2.0%

Shares of UTHR stock opened at $467.30 on Thursday. United Therapeutics Corporation has a 12 month low of $266.98 and a 12 month high of $519.99. The company has a market cap of $20.12 billion, a PE ratio of 17.71, a price-to-earnings-growth ratio of 2.56 and a beta of 0.84. The business’s 50 day moving average is $487.51 and its two-hundred day moving average is $418.60.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share for the quarter, topping the consensus estimate of $6.89 by $0.27. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The business had revenue of $799.50 million during the quarter, compared to analysts’ expectations of $812.87 million. During the same quarter in the previous year, the firm earned $6.39 EPS. The firm’s revenue was up 6.8% compared to the same quarter last year. As a group, equities analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Insider Transactions at United Therapeutics

In other news, COO Michael Benkowitz sold 22,500 shares of the company’s stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $429.25, for a total value of $9,658,125.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders sold 566,864 shares of company stock worth $269,514,607 in the last 90 days. Insiders own 10.30% of the company’s stock.

Analyst Upgrades and Downgrades

UTHR has been the topic of several research reports. UBS Group upped their price target on United Therapeutics from $600.00 to $645.00 and gave the company a “buy” rating in a report on Tuesday, January 6th. HC Wainwright boosted their target price on United Therapeutics from $500.00 to $525.00 and gave the stock a “buy” rating in a research report on Thursday, October 30th. Morgan Stanley set a $447.00 price target on United Therapeutics in a research report on Wednesday, October 29th. Wells Fargo & Company lifted their price target on United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 30th. Finally, Royal Bank Of Canada upped their price objective on shares of United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a research note on Thursday, October 30th. Eight equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $509.50.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.